DVLT: $10M deal could unlock genomic goldmine!

Introduction

Datavault AI Inc. (NASDAQ: DVLT) – formerly WiSA Technologies – is a small-cap tech company at the nexus of AI, blockchain, and data monetization. In November 2025, DVLT announced a $10 million exclusive licensing deal with Scilex Holding Company (NASDAQ: SCLX) to launch a blockchain-based “Biotech Exchange” platform (^[1]). This platform will tokenize and trade genomic and biotech assets (from DNA data to drug information), aiming to unlock value from vast genomic datasets. Under the agreement, DVLT receives a non-refundable $10 million license fee (paid in four $2.5 million installments through September 2026) and could earn up to $2.55 billion in milestone payments if Scilex achieves certain biotech asset sales targets (^[1]). DVLT touts this deal – and its patented technology for tokenizing DNA data (^[1]) – as a potential “genomic goldmine” that leverages its platform to monetize real-world biomedical data. This ambitious partnership comes on the heels of other strategic moves, including a $150 million strategic investment commitment from Scilex (to be paid in Bitcoin) aimed at accelerating DVLT’s data exchange infrastructure (^[2]) (^[2]). The flurry of deals has positioned DVLT in multiple high-growth arenas, but it has also drawn significant market scrutiny and volatility, underscoring the speculative nature of this emerging data-monetization play.

Dividend Policy & Yield

DVLT does not pay any dividend on its common stock, nor has it paid one historically (^[3]). As an early-stage, growth-focused tech company, DVLT reinvests any resources into developing its platform and patent portfolio rather than returning cash to shareholders. Management has explicitly stated they do not intend to pay cash dividends in the foreseeable future (^[3]). Instead, investors in DVLT must look to potential stock price appreciation for returns, which is inherently uncertain for a company at this stage. Traditional REIT metrics like FFO/AFFO are not applicable here, as DVLT is not a real estate or income-oriented firm but a speculative tech venture. In short, DVLT follows a growth-over-income strategy, with no dividend yield on offer to shareholders.

Leverage & Debt Maturities

Over the past two years, DVLT (and its predecessor WiSA) relied on convertible debt and equity issuance to fund operations (^[3]) (^[3]). The good news for creditors: DVLT recently strengthened its balance sheet by eliminating a chunk of debt. In October 2025, the company announced the full conversion of $13.3 million in long-term notes into equity, thereby substantially reducing outstanding debt obligations (^[4]). This conversion, along with prior repayments of legacy notes, leaves DVLT with minimal traditional debt aside from one major obligation: a $10 million convertible promissory note issued to EOS Holdings (the selling entity of Data Vault’s assets, led by DVLT’s CEO) (^[3]) (^[3]). This note carries a 5.12% annual interest rate and comes due in late 2027 (^[3]), but importantly it can convert to DVLT stock (at a 25% discount to market VWAP) if not repaid by maturity. In fact, an affiliate of the CEO has already converted $3.2 million of this note into 10 million DVLT shares (^[5]), signaling insider confidence and trimming the principal to roughly $6.8 million. With interest on the remaining note at about $0.35 million per year, DVLT’s interest burden is modest – and likely to be met from incoming capital. The new Scilex license deal provides scheduled inflows ($2.5 million by end of 2025) (^[1]), which will help service any interest and fund operations in the near term. Additionally, DVLT secured a $150 million equity infusion commitment from Scilex in Q4 2025 (payable in Bitcoin) to boost its supercomputing and exchange rollout (^[2]) (^[2]). This two-tranche investment (with an initial 15 million shares already issued and the remainder pending shareholder approval) will dramatically increase DVLT’s cash (or crypto) reserves and effectively make the company debt-light going forward. Overall, DVLT’s leverage profile has improved – legacy debts and convertibles have been largely paid off or converted, and new funding is coming as equity rather than loans. However, the trade-off is dilution (discussed below), and DVLT’s operating cash flow remains deeply negative, meaning the company is still dependent on external financing to cover expenses until it achieves profitability (^[3]) (^[3]).

Earnings Coverage & Cash Flow

DVLT is not yet profitable, so traditional coverage ratios are weak. The company’s net losses have been substantial, reflecting heavy R&D and one-time charges around its business combination. For 2024, DVLT reported a net loss of $51.4 million (widened from a $18.7 million loss in 2023) (^[3]), on only $2.7 million in revenue (^[3]). In other words, operating income is insufficient to cover interest expense or fixed charges, let alone support dividends. Any interest obligations on its debt (e.g. the ~5% on the EOS note) have effectively been paid using capital raises rather than earnings. The company’s cash burn was $17.5 million in 2024 operating activities (^[3]), and similar burn continued into 2025. This raises going-concern questions – indeed, auditors flagged “substantial doubt” about DVLT’s ability to continue without additional financing (^[3]) (^[3]). Management has addressed this by repeatedly raising capital (through stock offerings, note conversions, and now the Scilex deals). Thanks to these infusions, DVLT’s liquidity runway has extended: as of Q3 2025, the balance sheet is bolstered by new cash investments. But until meaningful revenues from data exchanges and licensing materialize, coverage of expenses relies on external funding, not internal cash generation. Investors should expect DVLT to lean on new equity or partnership payments to fund operations over the next 1–2 years (^[6]). In summary, DVLT’s current cash flows do not cover its costs – but recent deals aim to bridge that gap. The upcoming challenge is converting the hype into sustainable cash earnings to eventually achieve positive coverage of interest and operating costs.

Valuation & Comparables

Valuing DVLT is difficult given its nascent revenues and complex asset base. Traditional metrics like P/E are not meaningful (DVLT has negative earnings), so the market instead prices it on revenue multiples and intellectual property value. At recent prices, DVLT’s market capitalization has oscillated widely – roughly $90–$380 million in recent weeks, reflecting extreme volatility. Even at the lower end, shares trade at a lofty multiple of trailing sales. For context, DVLT’s revenue over the last 12 months is only a few million dollars (it logged $1.7 million in Q2 2025, up 467% year-on-year) (^[7]). This implies a trailing price-to-sales well into the double or triple digits. Such a valuation presumes explosive growth ahead. Management indeed forecasts “hypergrowth”: DVLT projects $12–$15 million in revenue in the second half of 2025 and $40–$50 million in 2026 (^[7]), fueled by licensing deals and new data exchange launches. If achieved, those targets would significantly improve the sales multiple (e.g. ~$45 million in 2026 sales would put the stock near 8× forward sales at a $360 million cap). Still, those outcomes are speculative. The market’s skepticism is evident – DVLT shares have experienced steep declines and rallies as news emerges. Notably, the stock is largely driven by retail traders; institutional ownership is under 1%, and only a few analysts cover the name (^[6]). Recent analyst price targets vary widely, but even the lowest (around $3) implied substantial upside from the sub-$2 levels in mid-October (^[6]). In terms of comparables, DVLT is something of a unique hybrid (part patent-licensing company, part blockchain data exchange). One could liken its valuation to other speculative AI/blockchain firms or small-cap IP licensing plays, which also trade more on future potential than current financials. Additionally, DVLT’s balance sheet carries significant intangible assets from its Data Vault acquisition (valued at ~$210 million) (^[8]) (^[8]). The stock recently traded below book value, suggesting investors discount a lot of that intangible value. For example, at $0.90 per share, DVLT’s market cap (~$100 million) was a fraction of its post-merger pro forma equity – indicating doubts about monetizing its 70+ patents or achieving projected revenue. Overall, DVLT’s valuation is highly speculative: bulls argue its patented exchanges and tokenization technology form a valuable platform (especially with partners like IBM and Nasdaq/NYIAX on board (^[6]) (^[9])), while bears point to the minimal revenue and heavy dilution. Until DVLT proves its business model and grows revenue as promised, expect its valuation to swing sharply on news and sentiment rather than fundamentals.

Risks and Red Flags

Investors in DVLT face numerous risks and red flags given the company’s early stage and unconventional strategies:

– Dilution & Share Count Explosion: DVLT’s aggressive financing deals are massively dilutive. The Scilex $150 million investment will issue up to 278.9 million new shares at ~$0.54 each (^[2]) – more than tripling the share count if fully approved. Insiders have also converted debt to equity at low prices (e.g. 10 million shares at $0.32 via the CEO’s affiliate) (^[5]). This dilution can erode existing shareholders’ ownership and has contributed to past reverse stock splits. Investors should brace for a much larger float and potential further equity raises before profitability (^[6]).

25,000%

The $50 Secret That Lets Robots See — Before October 23

One tiny eyesight supplier could be the key to Tesla's robot army. Jeff Brown names the ticker and why it matters.

Small company. Massive leverage. Time-sensitive.

Reveal the $50 Stock
Get the Full Report (Free)

– Continued Losses & Funding Uncertainty: DVLT is burning cash and has a history of operating losses (over $50 million net loss in 2024 alone) (^[3]). It will likely require additional funding to sustain operations until revenues ramp meaningfully (^[3]). While recent infusions (the Scilex cash and other financings) provide a lifeline, the company admitted that substantial doubt about its ability to continue as a going concern existed absent these deals (^[3]). If any planned funding falls through (e.g. if shareholders don’t approve the full Scilex second tranche), DVLT could face a cash crunch. In essence, the company’s viability hinges on external capital until its business model proves itself.

– Execution Risk – Unproven Revenue Model: The “genomic data goldmine” thesis remains unproven. DVLT’s huge milestone potential ($2.55 billion) is predicated on Scilex achieving high volume biotech transactions on a brand-new exchange (^[1]). It’s uncertain how quickly (or even if) pharma and biotech firms will adopt tokenized data trading. Similarly, DVLT’s other exchanges (for carbon credits, NIL rights, etc.) are upcoming and have no track record yet. Hitting the internally projected $40–$50 million revenue in 2026 will require rapid client adoption and scale-up that could be challenging in heavily regulated industries. Any delays or shortfalls in these initiatives would leave DVLT’s lofty growth targets unmet.

URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

– Volatility & Short-Seller Allegations: DVLT’s stock has been extremely volatile, and it attracted short-seller scrutiny in late 2025. Wolfpack Research released a highly critical short report accusing the company and CEO of misleading statements and overhyping its prospects (^[10]) (^[10]). The report coincided with a sharp drop in DVLT’s share price (nearly –20% on Oct. 31) (^[11]). DVLT’s management forcefully denied the allegations as “false and defamatory,” even announcing plans to pursue legal action against Wolfpack (^[10]) (^[10]). Still, the episode highlights perceptions of red flags – such as DVLT’s rapid tie-ups and promotional tone – that savvy short sellers are watching. The stock’s float remains small and short interest stands around 20% of float (^[6]), which can exacerbate swings. All told, DVLT is a high-volatility name, and negative reports (or even broad market risk-off sentiment) could trigger outsized declines.

– Crypto and Counterparty Risks: Unusually, DVLT’s major funding is coming in the form of Bitcoin. Scilex’s $150 million investment will be delivered in BTC at spot prices (^[2]). This exposes DVLT to cryptocurrency volatility and liquidity risk – Bitcoin’s value could swing significantly between agreement and usage of funds. Holding such a large crypto position on the balance sheet may also introduce accounting and security considerations. Additionally, DVLT is becoming deeply intertwined with Scilex (which will own a large equity stake and has two board seats) (^[2]) (^[2]). Any setbacks at Scilex (a small-cap biotech facing its own market and financing pressures) could spill over to DVLT. There is a strategic concentration risk in having one primary partner/investor for both capital and revenue. If Scilex were unable to fulfill its funding or license payments (for example, due to financial distress), DVLT would be severely impacted. Investors should monitor this symbiotic relationship closely.

🪙

Unlock Massive Bitcoin Profits — Without Buying Bitcoin

Larry Benedict reveals how skimmers have pocketed $4,898 (and more) without touching crypto wallets.

Get Larry's 3-Step Blueprint
See Case Studies ▸

Works on desktop & mobile — just tap the button to start your risk-managed trial.

– Regulatory and Data Privacy Hurdles: DVLT’s business aims to tokenize sensitive assets (genomic data, healthcare records, etc.) on blockchain exchanges. This innovative model faces regulatory uncertainty. Compliance with privacy laws (like HIPAA for medical data or GDPR internationally) and securities laws (if tokens are deemed securities) could impede or slow the rollout of DVLT’s exchanges. Any sign of regulatory pushback or need for additional safeguards could increase costs and delay revenues. While DVLT emphasizes its focus on privacy and security (^[3]) (^[3]), the risk of stricter regulation in the AI/crypto/data realm is a background concern that could constrain the “genomic goldmine” vision.

In sum, DVLT offers high upside potential but also multiple red flags. The combination of heavy dilution, ongoing losses, untested business models, and external skepticism (from short sellers and lack of institutional backing) makes this a speculative investment. Bulls are betting DVLT’s patents and partnerships will eventually generate robust cash flows, whereas bears warn that the current hype may not translate into shareholder value. Caution is warranted given the elevated risks outlined above.

Open Questions

Despite the recent deal excitement, several open questions remain about DVLT’s path forward:

– Can DVLT turn tech into revenue? – The company boasts a broad patent portfolio (70+ patents) and cutting-edge platforms, but it is still in the early innings of monetization. Will DVLT’s AI-driven exchanges and tokenization tech actually gain paying customers at scale? Investors will be watching upcoming revenue reports to see if the promised triple-digit growth is materializing beyond one-time license fees (^[7]) (^[7]).

– How quickly will the Biotech Exchange ramp up? – The Scilex partnership is crucial. An open question is how effectively Scilex can build and attract participants to the new Biotech Exchange using DVLT’s platform. Reaching the multi-billion-dollar sales milestones that unlock DVLT’s $2.55 billion contingent payments (^[1]) likely requires industry-wide adoption, not just one company’s use. It remains to be seen if this exchange can achieve critical mass in the competitive biotech/pharma data market.

– What is the plan for the legacy audio business? – DVLT’s Acoustic Science division (inherited from WiSA) holds valuable wireless audio IP (e.g. WiSA® and ADIO® technologies) (^[5]). However, the company’s narrative has shifted squarely to data exchanges and AI. Management has not clearly outlined how – or if – the audio hardware/licensing segment will contribute to growth. Will DVLT seek to monetize or divest these audio assets, or integrate them (e.g. ultrasonic data transmission via ADIO) into its data platforms? This is an area of uncertainty that could affect future revenues and margins.

– How will the $150 million Bitcoin investment be managed? – Once the Scilex equity investment closes, DVLT could find itself holding a large Bitcoin treasury. An open question is whether DVLT will convert the BTC to cash for operational use (and if so, when), or retain some as a strategic asset. The company’s plans for handling crypto volatility and any hedging strategy have not been detailed publicly. Moreover, shareholder approval for issuing the full 278+ million shares to Scilex is pending (^[2]) – investors must watch the upcoming vote and any potential adjustments to terms. The outcome will determine DVLT’s final capital structure and how much runway it truly has.

– Will projected revenues materialize without further dilution? – DVLT’s forecasts of ~$45 million in 2026 revenue (^[7]) are ambitious. Achieving that would greatly improve the financial picture. However, if growth falls short or takes longer, will DVLT need to raise more capital (and dilute shareholders yet again) to bridge the gap? The company’s ability to hit its revenue milestones – from the NYIAX advertising exchange deal to new tokenization platforms – in a timely manner is critical. Successful execution could mean the current financings carry it to self-sufficiency, whereas any disappointment might force additional stock or warrant offerings. This balance between growth and dilution remains an open question heading into 2026.

– What might Wolfpack be right about? – Lastly, the shadow of the short report raises questions about governance and transparency. DVLT has vociferously defended its integrity (^[10]) (^[10]), but investors will want to see independent validation of its technology and deals. For instance, how real is the uptake of DVLT’s platform among enterprise clients? Are there related-party complexities (given the CEO’s involvement in both DVLT and EOS Holdings) that merit scrutiny? As DVLT’s story unfolds, continued due diligence is needed to address any lingering concerns that have been raised by skeptics.

These open questions underscore that DVLT’s $10 million “genomic goldmine” deal is just the beginning. The company has secured valuable partners, patents, and capital – now it must deliver tangible results. In the coming quarters, clarity on these issues will be crucial for investors to gauge whether DVLT is on track to transform its bold vision into lasting shareholder value, or whether challenges will temper the goldmine into something more modest. Only time (and execution) will tell how this speculative bet plays out in the rapidly evolving intersection of genomics, AI, and blockchain.

Sources

For informational purposes only; not investment advice.